CN106565840B - 抗乙肝表面抗原的抗体及其用途 - Google Patents

抗乙肝表面抗原的抗体及其用途 Download PDF

Info

Publication number
CN106565840B
CN106565840B CN201610879693.5A CN201610879693A CN106565840B CN 106565840 B CN106565840 B CN 106565840B CN 201610879693 A CN201610879693 A CN 201610879693A CN 106565840 B CN106565840 B CN 106565840B
Authority
CN
China
Prior art keywords
seq
antibody
antigen
binding fragment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610879693.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106565840A (zh
Inventor
罗文新
周兵
张娟
袁权
张天英
张军
夏宁邵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yang Sheng Tang Co Ltd
Xiamen University
Original Assignee
Yang Sheng Tang Co Ltd
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd, Xiamen University filed Critical Yang Sheng Tang Co Ltd
Publication of CN106565840A publication Critical patent/CN106565840A/zh
Application granted granted Critical
Publication of CN106565840B publication Critical patent/CN106565840B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201610879693.5A 2015-10-09 2016-10-09 抗乙肝表面抗原的抗体及其用途 Active CN106565840B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015106479777 2015-10-09
CN201510647977 2015-10-09

Publications (2)

Publication Number Publication Date
CN106565840A CN106565840A (zh) 2017-04-19
CN106565840B true CN106565840B (zh) 2020-09-01

Family

ID=58487306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610879693.5A Active CN106565840B (zh) 2015-10-09 2016-10-09 抗乙肝表面抗原的抗体及其用途

Country Status (10)

Country Link
US (1) US10689434B2 (enExample)
EP (1) EP3360896B1 (enExample)
JP (2) JP6949012B2 (enExample)
KR (1) KR102132604B1 (enExample)
CN (1) CN106565840B (enExample)
AU (1) AU2016334290B2 (enExample)
BR (1) BR112018007121A2 (enExample)
CA (1) CA3001231C (enExample)
ES (1) ES3041684T3 (enExample)
WO (1) WO2017059813A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016334290B2 (en) * 2015-10-09 2020-06-18 Xiamen University Antibody to hepatitis B surface antigen and use thereof
MY208015A (en) * 2018-05-31 2025-04-07 Univ Tokyo Anti-human tlr7 antibody
CN112165974B (zh) * 2018-05-31 2024-11-08 诺华股份有限公司 乙型肝炎抗体
JP7454855B2 (ja) * 2018-12-21 2024-03-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
JP7607289B2 (ja) * 2019-05-23 2024-12-27 シァメン・ユニヴァーシティ 新規の抗ｂ型肝炎ウイルス抗体及びその使用
CN111242107B (zh) * 2020-04-26 2021-03-09 北京外号信息技术有限公司 用于设置空间中的虚拟对象的方法和电子设备
WO2024148263A1 (en) * 2023-01-06 2024-07-11 Victorian Infectious Diseases Reference Laboratory Methods and compositions for antibody treatment of hepatitis b infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
CN102906111A (zh) * 2009-12-24 2013-01-30 株式会社绿十字 特异性结合乙型肝炎病毒表面抗原的人抗体
CN103483421A (zh) * 2012-06-11 2014-01-01 厦门大学 用于治疗hbv感染及相关疾病的多肽及抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059318A1 (en) 2000-10-02 2002-08-01 Korea Research Institute Of Bioscience And Biotechnology A humanized antibody to surface antigen s of hepatitis b virus and a preparing method thereof
US9567390B2 (en) * 2008-01-23 2017-02-14 Department Of Biotechnology Humanized high affinity recombinant antibody against Hepatitis B surface antigen
CN102786592A (zh) * 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
WO2015107126A1 (en) * 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
AU2016334290B2 (en) * 2015-10-09 2020-06-18 Xiamen University Antibody to hepatitis B surface antigen and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
CN102906111A (zh) * 2009-12-24 2013-01-30 株式会社绿十字 特异性结合乙型肝炎病毒表面抗原的人抗体
CN103483421A (zh) * 2012-06-11 2014-01-01 厦门大学 用于治疗hbv感染及相关疾病的多肽及抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Human monoclonal antibody against Hepatitis B virus surface antigen (HBsAg);Yong-Won Shin等;《Antiviral Research》;20090831;第75卷(第2期);113-120 *

Also Published As

Publication number Publication date
EP3360896B1 (en) 2025-07-23
AU2016334290A1 (en) 2018-05-10
KR20180084045A (ko) 2018-07-24
US20190389939A1 (en) 2019-12-26
AU2016334290B2 (en) 2020-06-18
CA3001231C (en) 2022-07-12
CA3001231A1 (en) 2017-04-13
US10689434B2 (en) 2020-06-23
CN106565840A (zh) 2017-04-19
JP2018533937A (ja) 2018-11-22
JP2021063092A (ja) 2021-04-22
EP3360896A4 (en) 2019-08-28
WO2017059813A1 (zh) 2017-04-13
JP6949012B2 (ja) 2021-10-13
EP3360896A1 (en) 2018-08-15
KR102132604B1 (ko) 2020-07-13
ES3041684T3 (en) 2025-11-13
BR112018007121A2 (pt) 2018-11-06

Similar Documents

Publication Publication Date Title
US12077571B2 (en) Polyomavirus neutralizing antibodies
CN106565840B (zh) 抗乙肝表面抗原的抗体及其用途
CN115397852B (zh) 工程化抗il-2抗体
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
CN113480641B (zh) 用于治疗乙肝感染及相关疾病的抗体
JP2023528992A (ja) Ｈｉｖ－１抗体
JP2014526886A (ja) マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
TW202415677A (zh) 抗TNFα抗體及組合物
CN113549146A (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途
JP2025535498A (ja) Ｃｄ２４に対する抗体およびその使用
HK40059983A (en) Polyomavirus neutralizing antibodies
WO2024123897A1 (en) Broadly neutralizing and potent antibodies against hiv
CN119119268A (zh) Pvrig抗体及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant